Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis by McCool, Rachael et al.
                          McCool, R., Wilson, K., Arber, M., Fleetwood, K., Toupin, S., Thom, H., ...
Edwards, S. (2019). Systematic review and network meta-analysis comparing
ocrelizumab with other treatments for relapsing multiple sclerosis. Multiple
Sclerosis and Related Disorders, 29, 55-61.
https://doi.org/10.1016/j.msard.2018.12.040
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.msard.2018.12.040
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://www.sciencedirect.com/science/article/pii/S2211034818305807 . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Contents lists available at ScienceDirect
Multiple Sclerosis and Related Disorders
journal homepage: www.elsevier.com/locate/msard
Systematic review and network meta-analysis comparing ocrelizumab with
other treatments for relapsing multiple sclerosis
Rachael McCoola, Katy Wilsona, Mick Arbera, Kelly Fleetwoodb, Sydney Toupinb, Howard Thomc,
Iain Bennettd, Susan Edwardsd,⁎
a York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York YO10 5NQ, UK
bQuantics Biostatistics, West End House, 28 Drumsheugh Gardens, Edinburgh EH3 7RN, UK
c Bristol Medical School: Population Health Sciences, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
dHealth Economics and Evidence Synthesis, Global Access Center of Excellence, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, CH-4070, Switzerland
A R T I C L E I N F O
Keywords:
Relapsing multiple sclerosis
Disease-modifying therapy
Ocrelizumab
Systematic literature review
Network meta-analysis
Anti-CD20
A B S T R A C T
Background: Ocrelizumab was approved for the treatment of relapsing multiple sclerosis (RMS) and primary
progressive multiple sclerosis (PPMS) by the US Food and Drug Administration in March 2017 and by the
European Medicines Agency in January 2018. These approvals were based on two pivotal randomized controlled
trials (RCTs), OPERA I and OPERA II, comparing ocrelizumab 600mg with an active comparator, interferon β-1a
44 μg (Rebif), and the first trial with positive results in patients with PPMS, which compared ocrelizumab with
placebo. However, direct evidence of the efficacy and safety of ocrelizumab in RMS compared with other dis-
ease-modifying therapies (DMTs) approved for RMS is not available from RCTs. In the absence of such RCTs,
network meta-analyses (NMAs) were conducted to compare indirectly the relative efficacy and safety of ocre-
lizumab with all other approved DMTs for the treatment of RMS.
Methods: Systematic literature searches were conducted in MEDLINE, Embase, the Cochrane Library, trial reg-
isters, relevant conference websites and health technology assessment agency websites. Eligible RCTs evaluated
approved treatments for multiple sclerosis (MS) in which more than 75% of patients had a relapsing form of MS.
NMAs were conducted for four efficacy and three safety outcomes, and treatment hierarchies were generated for
each outcome using surface under the cumulative ranking curve (SUCRA) values.
Results: Results suggest that ocrelizumab has superior efficacy to 10 of the 17 treatments in the 12-week con-
firmed disability progression network and 12 of the 17 treatments in the annualized relapse rate network (both
including placebo). The efficacy of ocrelizumab was comparable with the other treatments in both networks. In
the serious adverse events and discontinuation due to adverse events networks, ocrelizumab demonstrated a
safety profile comparable with all other treatments (including placebo). SUCRA values consistently ranked
ocrelizumab among the most effective or tolerable treatments across all outcomes.
Conclusions: Results suggest that ocrelizumab has an efficacy superior to or comparable with all other currently
approved DMTs across all endpoints analyzed, and a similar safety profile, indicating it offers a valuable package
for the treatment of patients with RMS.
1. Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease, char-
acterized by inflammation of the central nervous system that leads to
progressive neuro-axonal degeneration (Lavery et al., 2014). There is
no cure for MS, but 14 disease-modifying therapies (DMTs; following
the withdrawal of daclizumab from the market on 30 April 2018, it is
currently 13) have been approved by the European Medicines Agency
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(EMA) for the treatment of patients with relapsing forms of MS (RMS).
These DMTs aim to slow progression of disability, reduce the number
and severity of relapses, and diminish the impact of MS on health-re-
lated quality of life (Torkildsen et al., 2016). Selection of treatment
requires a compromise between the efficacy and safety profiles, which
vary across treatments. Given that DMTs with higher efficacy are often
associated with increased risk of serious adverse events (SAEs), they are
usually reserved for use later in the disease course (Gajofatto, 2015).
However, recent evidence suggests that early treatment with high-ef-
ficacy DMTs may lead to improved disease control (Merkel et al., 2017;
Rotstein et al., 2015).
Comparisons of efficacy and safety across different DMTs are needed
to inform treatment decisions for patients with MS. Head-to-head ran-
domized controlled trials (RCTs) are the gold standard for generating
this evidence. However, a single RCT of all DMTs has not been con-
ducted. In the absence of such a trial, network meta-analyses (NMAs)
can be used to compare treatments using both direct comparisons of
interventions within clinical trials and indirect comparisons based on a
common comparator, often placebo (Li et al., 2011). Several such NMAs
have compared the different DMTs for RMS (Fogarty et al., 2016;
Huisman et al., 2017; Institute for Clinical and Economic Review, 2017;
Tolley et al., 2015; Tramacere et al., 2015; Tsivgoulis et al., 2015;
Siddiqui et al., 2017; Melendez-Torres et al., 2017). However, these
NMAs have used differing methodologies, have not used all available
data by combining hazard ratio and count data, (Watkins, 2018) and
did not consider the trade-off between efficacy and safety with surface
under the cumulative ranking curve (SUCRA) values.
Ocrelizumab is a humanized anti-CD20 monoclonal antibody ap-
proved by the EMA in January 2018 for the treatment of adult patients
with RMS with active disease (defined by clinical or imaging features),
(European Medicines Agency (EMA), 2018) and has been received by
over 70,000 patients worldwide since US Food and Drug Administration
approval in March 2017 (Hoffmann-La Roche Ltd, 2018). The objective
of this study was to conduct a systematic literature review (SLR) and
NMA to evaluate the relative efficacy and safety of ocrelizumab com-
pared with all approved DMTs for the treatment of patients with RMS,
across seven measures of efficacy and safety.
2. Materials and methods
2.1. Identification and selection of relevant trials
An SLR was performed following National Institute of Health and
Care Excellence (NICE) guidelines to identify all RCTs assessing the
efficacy and safety of DMTs used for the treatment of patients with RMS
(National Institute for Health and Care Excellence (NICE), 2015).
Searches for relevant trials were conducted in October 2014, with up-
dates performed in November 2016 and July 2017. (Appendix A.1;
Table D1; Table D2). The review protocol was not registered.
Following identification of records, duplicates were removed, and
titles and abstracts were screened against the eligibility criteria; full
texts of the included records were then reviewed in a second review
round, against the same criteria. Both rounds of screening were carried
out by two independent reviewers, with disagreements resolved by a
third. Eligibility criteria included trials with a duration of at least 12
weeks, evaluating suitable interventions in which more than 75% of
patients had RMS (Table D3). Eligible interventions are listed in Table
D3. These included both doses of cladribine (3.5mg/kg and 5mg/kg),
which had received a positive opinion from the Committee for
Medicinal Products for Human Use at the time of analyses (July 2017).
Since analysis, only the 3.5mg/kg dose has been approved by the EMA.
Similarly, daclizumab was included because it was approved at the time
of analyses, but has since been withdrawn by the manufacturer because
of concerns surrounding its benefit-risk profile.
2.2. Data extraction and risk of bias
For trials that met the eligibility criteria, data relating to trial design
and methodology, details of interventions, patient eligibility criteria
and baseline characteristics, and outcome measures were extracted.
Data were extracted for the intent-to-treat (ITT) populations of the trials
and for the highly active and rapidly evolving severe RMS subgroups.
The risk of bias in each individual trial was assessed using the Cochrane
Risk of Bias Tool (Appendix A.2; Table D4) (Higgins et al., 2011).
2.3. Network meta-analyses
The key efficacy outcomes of interest for the NMAs were 12-week
confirmed disability progression (12-week CDP) and annualized relapse
rate (ARR; the primary outcome of most phase 3 clinical trials in MS,
including the OPERA I and OPERA II ocrelizumab trials). The key safety
outcomes of interest were SAEs and discontinuation of treatment due to
an adverse event (AE). In addition, the following outcomes were also
analyzed: 24-week confirmed disability progression (24-week CDP),
proportion of patients who remained relapse-free and all-cause dis-
continuation of treatment. A feasibility assessment was conducted to
assess the similarity of the trials (Appendix A.3) (Dias et al., 2011b).
Trials which were suitably similar were included in the NMAs, pro-
viding there was sufficient similarity across the definitions of the out-
comes (Appendix A.4; Table D5).
All outcomes were analyzed using standard Bayesian approaches as
described in the NICE Decision Support Unit Technical Support
Document (DSU TSD) 2 (Appendix A.5) (Dias et al., 2011b). The
analyses used the ITT population results, where available. The base-
case analyses used random effects models because these are considered
more appropriate than fixed effect models when there is heterogeneity
between patient populations across trials. Three types of model were
applied for the base-case analysis, depending on the outcome: (i) a
survival model for 12-week CDP and 24-week CDP; (ii) a Poisson model
for ARR; and (iii) a binomial model for proportion of patients relapse-
free and the three safety outcomes (SAEs, discontinuation due to AEs
and all-cause discontinuation). For the between-trial variance, in-
formative prior distributions were assumed following Turner et al. for
both the survival and binomial models, with a vague prior distribution
assumed for the Poisson models (Appendix A.5.4) (Turner et al.,
2015). Vague prior distributions were used for all other parameters.
The input data and code used for each outcome are presented in Ap-
pendix A.5.6 and Tables D8–D14.
2.4. Sensitivity analyses and network meta-regressions
For each outcome, two sensitivity analyses were conducted to
evaluate the assumptions of the base-case NMA: (i) a fixed effect model
instead of a random effects model and (ii) a random effects model with
a different prior distribution for the between-trial variance. These were
vague priors for the survival and binomial models, and an alternative
vague prior for the Poisson model (Appendix A.5.4). For each out-
come, meta-regression was also used to explore whether the time at
which outcomes were observed (i.e. follow-up time, on a continuous
scale) influenced the relative treatment effects.
To compare the fit of the base-case models to the data with the
sensitivity analyses and the meta-regression models, posterior mean
residual deviance and deviance information criterion (DIC) values were
calculated.
2.5. Heterogeneity and inconsistency assessments
Heterogeneity and inconsistency assessments were conducted for
the base-case NMAs (Appendix A.5.8). The I2 statistic was used to
measure heterogeneity, with thresholds of 0–40%, 30–60%, 50–90%
and 75–100% corresponding to “might not be important”, “may
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represent moderate heterogeneity”, “may represent substantial hetero-
geneity”, and “considerable heterogeneity”, respectively, according to
the Cochrane Handbook (Higgins et al., 2011). Inconsistency was
evaluated by comparing the DIC values of the base-case NMA model to
an inconsistency model as recommended in the NICE DSU TSD 4
(Dias et al., 2011a).
2.6. Surface under the cumulative ranking curve (SUCRA)
The probabilities of a treatment being at each possible rank were
summarized using SUCRA values (Salanti et al., 2011). To demonstrate
the efficacy and safety profile of each treatment, SUCRA values for the
two key efficacy outcomes (12-week CDP and ARR) and two key safety
outcomes (SAE and discontinuation due to AEs) were plotted on a radar
plot. SUCRA values range from 0% (the treatment is certainly ranked
last) to 100% (the treatment is certainly ranked first; Appendix A.5.9).
A similar approach was reported by Tramacere et al. (2015) although
SUCRA values on only two dimensions were considered.
2.7. Analysis
All analyses were conducted using Just Another Gibbs Sampler
(JAGS) version 4.1.0 or above, and R version 3.1.2 or above. The
package R2JAGS was used to run JAGS from within R (Plummer, 2018;
R Development Core Team 2018; Su and Yajima, 2018).
3. Results
After full text review of records identified in the SLR, a total of 183
records met the eligibility criteria for inclusion in the NMA, relating to
46 RCTs (Fig. 1). Of these 46, two RCTs were excluded for in-
appropriate treatment regimens/doses, and a further 11 RCTs with
duration less than 48 weeks were excluded, as these trials were not
designed to study clinical outcomes and were therefore considered too
different from the other trials for inclusion in NMAs (Appendix B.2;
Table D6). Therefore, 33 trials were included (Table D7; Table D17).
Analysis of RMS subgroup data is not reported here because: (i) of is-
sues with publication bias (favourable subgroups are more likely to be
reported); (ii) of breaking of randomization in NMAs when subgroup
data are used; and (iii) data were not reported by many of the trials, so
the resulting networks were disconnected. Results for all outcomes
versus placebo are presented in Appendix B.3.1 (Table D16; Table
D18).
3.1. Key efficacy and safety outcomes
3.1.1. 12-week confirmed disability progression network
The base-case network for 12-week CDP included 17 different
treatments, including placebo, from 22 trials (Table D7). Comparisons
of ocrelizumab versus other DMTs provided evidence that ocrelizumab
was more effective in reducing the risk of 12-week CDP than 10 other
treatments, including placebo (95% credible intervals below 1; (Fig. 2,
panel a; Appendix B.3.1; Table D15). The probability ocrelizumab was
more effective than the six remaining treatments was greater than 50%
in each case. There was no evidence to suggest any treatment was more
effective than ocrelizumab.
3.1.2. Annualized relapse rate network
The base-case network for ARR included 17 different treatments,
including placebo, from 30 trials (Table D7). Etemadifar et al., was
excluded because it reported insufficient data on the ARR
(Etemadifar et al., 2006). Comparisons of ocrelizumab versus other
DMTs provided evidence that ocrelizumab was more effective in re-
ducing the ARR than 12 other treatments, including placebo (Fig. 2,
panel b; Appendix B.3.1; Table D15). The probability ocrelizumab was
more effective than two of the four remaining treatments was greater
than 50% in each case. There was no evidence to suggest any treatment
was more effective than ocrelizumab.
3.1.3. Serious adverse events network
The base-case network for serious adverse events included 17 dif-
ferent treatments (including placebo) from 24 trials (Table D17).
Comparisons of ocrelizumab versus other DMTs showed that there was
no evidence of a difference between ocrelizumab and any other treat-
ments in the risk of SAEs (Fig. 2, panel c).
Fig. 1. Flow of information for identification of studies in the systematic literature review.
R. McCool et al. Multiple Sclerosis and Related Disorders 29 (2019) 55–61
57
3.1.4. Discontinuation due to adverse events
The base-case network for discontinuation due to adverse events
included 18 different treatments (including placebo) from 31 trials
(Table D17). Comparisons of ocrelizumab versus other DMTs showed
that there was no evidence of a difference between ocrelizumab and
any other treatments in the discontinuation of treatment due to AEs
(Fig. 2, panel d).
3.1.5. Sensitivity analyses and meta-regressions
The results of the base-case NMAs of the key efficacy and safety
outcomes were robust to sensitivity analyses and meta-regressions
(Table D19). The DIC values for sensitivity analyses 1 and 2 were not
different enough (i.e. more than± 3) from the base-case DIC values to
be considered meaningful. For each of these outcomes, the DIC values
suggest that meta-regression did not improve the model fit over the
base-case model (Table D19), indicating follow-up time did not modify
the relative treatment effects from the base-case NMA, or at least that
these models could not demonstrate such an effect (Welton et al.,
2012).
3.1.6. Heterogeneity and inconsistency assessments
Most pairwise comparisons had heterogeneity which “might not be
important” (I2 statistics less than or equal to 40%) (Higgins et al.,
2011). The consistency models had lower or similar DIC values com-
pared with the inconsistency models, indicating no evidence of incon-
sistency in the networks (Appendix B3.3.3; Table D19).
3.2. Surface under the cumulative ranking curve (SUCRA) radar plot
The SUCRA value rankings reflect the above results and are reported
in Table 1. When the probabilities for the two key efficacy outcomes
were plotted alongside the two key safety outcomes to provide an
overview of all available comparative evidence, ocrelizumab demon-
strated a consistently high probability of being ranked as the most ef-
fective or tolerable treatment across all four outcomes (Fig. 3).
3.3. Other outcomes analyzed
The base-case network for 24-week CDP included 15 different
treatments, including placebo, from 21 trials (Table D7), excluding the
INCOMIN trial because the 24-week CDP result is regarded as an outlier
by MS experts and neurologists (Vartanian, 2003). Comparisons of
ocrelizumab versus other DMTs provided evidence that ocrelizumab
was more effective in reducing the risk of 24-week CDP than placebo,
interferon β-1a 44 μg (Rebif) and teriflunomide 7mg (Appendix B3.1;
Fig. D3, panel a; Table D15). The base-case network for the
Fig. 2. Base-case forest plots for ocrelizumab versus other DMTsa for 12-week CDP (panel a), ARR (panel b), SAEs (panel c) and discontinuation due to AEs (panel d).
aFor treatments for which data were available. The numbers next to the brackets on the right of each panel represent the jumps in the network between ocrelizumab
and the other treatments. AE, adverse event; ARR, annualized relapse rate; CDP, confirmed disability progression; DMT, disease-modifying therapy; i.m., in-
tramuscular; SAE, serious adverse event; s.c., subcutaneous.
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Table 1
Treatment ranking tables ordered by SUCRA values for key efficacy and safety outcomes.a
Annualized relapse rate 12-week confirmed disability progression Serious adverse events Discontinuation due to adverse events
Treatment ranking % Treatment ranking % Treatment ranking % Treatment ranking %
Alemtuzumab (12mg) 98.0 Ocrelizumab (600mg) 95.5 Interferon β-1b (250 μg, s.c.) 81.3 Alemtuzumab (12mg)a 93.9
Natalizumab (300mg) 92.7 Alemtuzumab (12mg) 91.9 Ocrelizumab (600mg) 78.7 Placebo 86.6
Ocrelizumab (600mg) 88.9 Natalizumab (300mg) 71.2 Glatiramer acetate (20mg) 72.9 Fingolimod (0.5mg) 82.0
Cladribine (3.5 mg/kg) 75.3 Daclizumab (150mg) 66.0 Pegylated interferon β-1a (125 μg) 71.4 Dimethyl fumarate (240mg) 64.4
Daclizumab (150mg) 70.3 Pegylated interferon β-1a (125 μg) 59.6 Interferon β-1a (30 μg i.m.) 71.1 Natalizumab (300mg) 63.9
Cladribine (5.25mg/kg) 69.8 Interferon β-1a (44 μg, s.c.) 58.1 Daclizumab (150mg) 66.1 Teriflunomide (7mg) 60.6
Fingolimod (0.5 mg) 67.8 Dimethyl fumarate (240mg) 53.9 Natalizumab (300mg) 64.2 Ocrelizumab (600mg) 60.0
Dimethyl fumarate (240mg) 60.4 Cladribine (3.5 mg/kg) 52.5 Dimethyl fumarate (240mg) 60.6 Interferon β-1a (30 μg i.m.) 57.3
Interferon β-1a (44 μg, s.c.) 40.3 Cladribine (5.25mg/kg) 49.1 Interferon β-1a (44 μg, s.c.) 55.6 Glatiramer acetate (20mg) 54.8
Pegylated interferon β-1a (125 μg) 36.6 Teriflunomide (14mg) 47.6 Alemtuzumab (12mg) 51.1 Cladribine (3.5 mg/kg)a 49.3
Glatiramer acetate (40mg) 34.2 Interferon β-1a (22 μg, s.c.) 47.0 Fingolimod (0.5 mg) 40.4 Teriflunomide (14mg) 48.3
Teriflunomide (14mg) 34.2 Fingolimod (0.5mg) 40.5 Glatiramer acetate (40mg) 35.6 Interferon β-1a (22 μg, s.c.) 44.4
Glatiramer acetate (20mg) 33.2 Interferon β-1a (30 μg i.m.) 33.2 Placebo 29.1 Daclizumab (150mg) 35.3
Interferon β-1b (250 μg, s.c.) 26.8 Glatiramer acetate (20mg) 32.0 Teriflunomide (14mg) 26.2 Glatiramer acetate (40mg) 29.2
Teriflunomide (7mg) 13.0 Interferon β-1b (250 μg, s.c.) 31.0 Teriflunomide (7mg) 20.9 Interferon β-1b (250 μg, s.c.) 25.2
Interferon β-1a (30 μg i.m.) 8.4 Teriflunomide (7mg) 18.8 Cladribine (3.5 mg/kg) 14.7 Interferon β-1a (44 μg, s.c.) 22.2
Placebo 0.0 Placebo 2.2 Cladribine (5.25mg/kg) 10.0 Pegylated interferon β-1a (125 μg) 13.5
Cladribine (5.25mg/kg)a 9.1
CDP, confirmed disability progression; i.m., intramuscular; s.c., subcutaneous; SUCRA, surface under the cumulative ranking curve.
a Because SUCRA values take into account the probability of a treatment being ranked in each position, a treatment with high probabilities of being second, third
etc. could still have a high SUCRA value.
Fig. 3. Radar plot of treatment rankings based on SUCRA values for key efficacy and safety outcomes.a aFor each outcome, treatments towards the outer edge of the
plot have SUCRA probabilities closer to 100% and are therefore more effective or more tolerable relative to the other treatments considered. Only treatments which
reported on all four outcomes are included in this radar plot (daclizumab was excluded as it was no longer marketed at the time of publication). i.m., intramuscular;
s.c., subcutaneous; SUCRA, surface under the cumulative ranking curve.
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proportion relapse-free included 18 different treatments, including
placebo, from 31 trials (Table D7). Comparisons of ocrelizumab versus
other DMTs provided evidence that patients receiving ocrelizumab
were more likely to remain relapse-free than 14 of the treatments, in-
cluding placebo (Appendix B3.1; Fig. D3, panel b; Table D15). For
all-cause discontinuation of treatment, the comparison of 17 treatments
in 26 trials (Table D17) provided evidence to suggest that patients who
receive ocrelizumab are less likely to discontinue than patients who
receive pegylated interferon β-1a or interferon β-1a 44 μg (Rebif), but
are more likely to discontinue than patients who receive alemtuzumab
or natalizumab (Appendix B3.1; Fig. D3, panel c).
Most pairwise comparisons had heterogeneity which “might not be
important” (Higgins et al., 2011), there was no evidence of incon-
sistency, and the base-case NMAs were robust to sensitivity analyses
(Appendix B3.2; Table D19). The SUCRA value rankings for 24-week
CDP, proportion relapse-free and all-cause discontinuation of treatment
are presented in Appendix B.3.4 and Table D21.
4. Discussion
Ocrelizumab has proven efficacy versus interferon β-1a 44 μg
(Rebif) in the pivotal trials OPERA I and OPERA II (Hauser et al., 2017).
However, direct comparisons of ocrelizumab with all other DMTs have
not been conducted. Therefore, we estimated relative treatment effects
for ocrelizumab versus all DMTs currently approved for the treatment
of RMS, by examining four efficacy and three safety outcomes in NMAs.
These models and the SUCRA ranking values calculated from them
suggest that ocrelizumab has an efficacy and safety profile that is su-
perior to or comparable with other available DMTs across all outcomes,
except natalizumab and alemtuzumab for one safety outcome: all-cause
discontinuation. When interpreting these all-cause discontinuation re-
sults, it is necessary to consider possible bias from the inability to dis-
continue induction treatments once the induction phase has been
completed, and the fact that patients were not blinded to the treatment
in some pivotal open-label trials. Ocrelizumab provides a treatment
option that demonstrates consistent efficacy and safety across all ana-
lyzed outcomes (Figs. 2, 3 and D3).
The 12-week CDP model provided evidence that ocrelizumab was
more effective than 10 treatments, while the 24-week CDP model
provided evidence that ocrelizumab was more effective than placebo,
interferon β-1a 44 μg (Rebif) and teriflunomide 7mg, based on the 95%
credible intervals. When interpreting these results, it should be con-
sidered that the 24-week CDP network has less power to detect a dif-
ference between treatments, evidenced by the wider credible intervals
for 24-week CDP (Fig. D3, panel a) than 12-week CDP (Fig. 2, panel
a). This is attributable to two things. First, 24-week CDP is, by defini-
tion, a rarer event than 12-week CDP. Second, the interconnectedness is
greater and there are fewer jumps between ocrelizumab and the other
treatments in the 12-week CDP, which decreases the uncertainty in the
NMA (Lu, 2004) (Fig. D1).
Several NMAs have been performed to compare the treatment ef-
fects of DMTs in MS (Fogarty et al., 2016; Huisman et al., 2017;
Institute for Clinical and Economic Review, 2017; Tolley et al., 2015;
Tramacere et al., 2015; Tsivgoulis et al., 2015; Siddiqui et al., 2017;
Melendez-Torres et al., 2017). Most recently in November 2017, Sid-
diqui et al. compared efficacy across five outcomes: ARR, 12-week CDP,
24-week CDP, proportion relapse-free, no evidence of disease activity
(NEDA) and a single combined safety outcome (any AEs) (Siddiqui
et al., 2017). These analyses were performed in active relapsing-re-
mitting MS (RRMS) and a subgroup with high disease activity. This
manuscript made different analysis assumptions, including the inclu-
sion of trials with a shorter duration in the ARR network but the ex-
clusion of trials under 24 months from the CDP NMAs; they also ran an
NMA on the NEDA endpoint despite differences in imaging definitions
and monitoring timepoints across trials. In addition, the treatment
rankings in Siddiqui et al. were based on the point estimates of
treatment effect in the NMAs, which, unlike the SUCRA approach re-
ported here, do not consider the uncertainty of these ranking estimates.
In March 2017, the Institute for Clinical and Economic Review
(ICER) report compared efficacy across two outcomes: CDP, which was
analyzed with 12-week and 24-week CDP combined, and ARR
(Institute for Clinical and Economic Review, 2017). Although results
were similar to the analysis reported here, there were differences in
methodology. First, ICER did not analyze the proportion relapse-free,
and only compared absolute safety outcomes; despite ICER's emphasis
of the benefit-risk profiles, ratings seem biased towards efficacy and
analysis of safety was limited. Second, the ICER report used event
counts for the combined CDP network, whereas this analysis used all
available data by combining hazard ratio and count data
(Watkins, 2018). Finally, the ICER report included rituximab, used off-
label for treatment of RMS, with no approved dose (which was un-
derpowered compared with other treatments in the ARR network), and
excluded cladribine, which has since been approved by the EMA.
Fogarty et al. also conducted an NMA for the DMTs approved for the
treatment of RRMS up to 2016, and found similar results to the analyses
reported here (Fogarty et al., 2016). However, ocrelizumab was not
included, because it had not been approved at the time of analysis, and
safety outcomes were not considered. Similarly, Tramacere et al. (2015)
carried out an NMA for RRMS and analyzed 12-week CDP and 12- and
24-month ARR. Although they considered ARR at two different times,
they analyzed only a single safety outcome: withdrawal due to AEs.
Neither of these publications analyzed the proportion relapse-free,
meaning this analysis is the only peer-reviewed NMA to consider both
this outcome and extensive safety outcomes, while including all cur-
rently approved DMTs for RMS based on a recent literature review (July
2017).
5. Strengths and limitations
The large number of RCTs reporting data for RMS treatments al-
lowed NMAs assessing all currently approved DMTs. Analyses were
performed following the NICE DSU TSDs (Dias et al., 2011b), which
provide guidelines for many of the statistical methods used for this
analysis. Assessments were made to evaluate whether risk of bias in
trials and heterogeneity between trials for each outcome was acceptable
(Dias et al., 2011b). SUCRA values were generated alongside the NMAs
and provided a more complete overview of all relative comparative
evidence. These strengths allowed robust comparisons that can be used
to inform reimbursement and treatment decisions.
NMAs of safety outcomes are limited by several factors, including:
(i) no trials were statistically powered to analyze safety; (ii) events
included were only those recorded during the trial period; and (iii) it is
unclear how an induction treatment can be discontinued, which im-
pacts the discontinuation due to AEs and all-cause discontinuation
networks. There were several further limitations of this analysis shared
by previously published NMAs. First, the validity of these analyses
depends on the appropriateness of assuming similarity across trials (e.g.
variation in definitions, follow-up time and baseline characteristics).
Trial heterogeneity was assessed with sensitivity analyses and meta-
regression, which generally agreed with the base-case results. Second,
some results were uncertain owing to the limited data available in the
networks, and there is risk of bias (the impact of which may have been
large if the comparison was central to the network) due to trials that
were not double-blinded or reported unexpected dropouts, and missing
or inappropriate ITT analyses. Third, the short-term results obtained
from RCTs analyzed in this report may not be relevant to longer-term
outcomes (i.e. beyond 24 months). Finally, the trials included in all
NMAs have been conducted over three decades (since 1987), during
which time the natural history of MS has changed; comparing con-
temporary trials with older trials is likely to result in differential
background rates of relapse. In addition, this has led to networks
centred around different comparator nodes (e.g. placebo and
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interferons) and relying on multiple trials to connect treatments of in-
terest (Fig. 2; Fig. D1; Fig. D3).
6. Conclusion
The favourable results of OPERA I and OPERA II demonstrated the
efficacy and safety of ocrelizumab in a direct comparison with inter-
feron β-1a 44 μg (Rebif 44mg). In the absence of head-to-head trials
against other DMTs for the treatment of patients with RMS, this NMA
provides important evidence on the relative efficacy and safety of
ocrelizumab compared with other approved treatments for RMS. This
evidence suggests that ocrelizumab has an efficacy superior to or
comparable with all other currently approved DMTs across all end-
points analyzed, and a similar safety profile, indicating that it offers a
complete and valuable package for the treatment of patients with RMS.
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